11/16/2026 | Press release | Distributed by Public on 11/16/2026 20:45
Andrew Dauber, MD, MMSc, chief of Endocrinology, was featured in the Rolling Stone, about the controversial use of erda, a cancer drug, by young people seeking to increase their height.
In the interview, Dr. Dauber discussed the appropriate use of growth hormone in children and debate among endocrinologists over when off-label treatment may be warranted.
"I've spoken to a lot of pediatric endocrinologists, and some say, 'Listen, I know they're going to get it. They're either going to get it off the internet or they're going to go see a doctor who doesn't know as much about it, and I feel like I should just give it to them and at least monitor them for safety and do it in a safer way,'" Dr. Dauber said.
He also warned about the risks of using erda for growth, which he said is too dangerous to prescribe for that purpose.
"That's way too dangerous" he said. "We only know about it at the chemotherapeutic doses."
To learn more, read the full article in the Rolling Stone or Yahoo News.